All News

The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.

Rodica Di Lorenzo, MD, explains why new headaches, migraine with aura, estrogen exposure, smoking, and pregnancy matter in stroke assessment.

Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.

The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.

A urologist discusses how primary care clinicians can identify patients most likely to benefit from prostate cancer screening while limiting overdiagnosis.

Axsome has launched the SUMMIT phase 3 clinical trial evaluating AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.

A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.

Brief speech, motor, vision, or balance changes may signal a TIA and require urgent evaluation, Rodica Di Lorenzo, MD, tells Patient Care Online.

Rodica Di Lorenzo, MD, of the Cleveland Clinic, reviews hypertension, lipids, diabetes, smoking, atrial fibrillation, and wearables in first-stroke prevention.

FDA awarded DT120 Breakthrough Therapy designation for MDD based on phase 3 data showing rapid, sustained improvement after one 100 μg dose.

Experts weigh GLP-1 therapy's promise for PMOS against the risks of overly rapid weight loss in teenagers.

Semaglutide brought 40.4% of children below the obesity BMI threshold, according to top-line results from the phase 3 STEP Young clinical trial.

Experts break down which labs actually change PMOS management and how to avoid diagnostic pitfalls.

US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.

Most patients meet PMOS in a primary care office first. Our experts map the referral threshold and argue insulin resistance — not just androgens — should drive how aggressively PCPs treat.

FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.

Our expert panel walks through the 2-criteria threshold for adolescents, the "at risk" category, and why untreated menstrual irregularity carries real long-term consequences.

A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.